SCHEMBL279734

SCHEMBL279734

Cc1cnc(C(=O)CNc2ccnnc2)s1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.36
RAB9A P51151 4/20 0.35
NPC1 O15118 3/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
ALDH1A1 P00352 2/20 0.34
PSMB5 P28074 2/20 0.34
SMYD3 Q9H7B4 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.33
HTT P42858 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280362 0.81 KMT2A (0.42) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3705884 0.67 SMYD3 (0.42) SMN1; SMN2RAB9ANPC1PKMKMT2A
SCHEMBL4853407 0.67 GSK3B (0.39) SMN1; SMN2RAB9ANPC1PKMKMT2A
SCHEMBL12124452 0.66 SMN1; SMN2 (0.57) SMN1; SMN2RAB9ANPC1PKMMAPT
Bromide SCHEMBL6169340 0.65 SMYD3 (0.38) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL12844929 0.65 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL30571106 0.65 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL22509130 0.64 RAB9A (0.40) SMN1; SMN2RAB9ANPC1PKMKMT2A
SCHEMBL3822625 0.64
SCHEMBL21955983 0.64 SMN1; SMN2 (0.39) SMN1; SMN2RAB9ANPC1PKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL SMN1; SMN2 1437/4885RAB9A 2458/4885NPC1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.